Why We Should Be Willing to Pay for Hepatitis C Treatment

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 10, 2015, Pages 1711-1713

  Chhatwal, Jagpreet ^a   Chen, Qiushi ^b   Kanwal, Fasiha ^c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Georgia Institute of Technology   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

BUDGET; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; QUALITY ADJUSTED LIFE YEAR; SUSTAINED VIROLOGIC RESPONSE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEPATITIS C, CHRONIC; TRANSMISSION;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS;

EID: 84941652406     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.06.005     Document Type: Editorial

References (21)

1. Kabiri M., Jazwinski A.B., Roberts M.S., et al. The changing burden of hepatitis C in the United States: model-based predictions. Ann Intern Med 2014, 161:170-180.
2. Sussman N.L., Remien C.H., Kanwal F. The end of hepatitis C. Clin Gastroenterol Hepatol 2014, 12:533-536.
3. Hoofnagle J.H., Sherker A.H. Therapy for hepatitis C-the costs of success. N Engl J Med 2014, 370:1552-1553.
4. Knox R. 1,000 pill for hepatitis C spurs debate over drug prices. NPR. December 30, 2014. Available: . Accessed: March 21, 2014. http://www.npr.org/blogs/health/2013/12/30/256885858/-1-000-pill-for-hepatitis-c-spurs-debate-over-drug-prices.
5. Japsen B. As pricey hepatitis pill Harvoni joins Sovaldi, states erect Medicaid hurdles. Forbes. Available: . Accessed: February 4, 2015. http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/.
6. Silverman E. What the 'shocking' Gilead discounts on its Hepatitis C drugs will mean. The Wall Street Journal. Available: . Accessed: February 4, 2015. http://blogs.wsj.com/pharmalot/2015/02/04/what-the-shocking-gilead-discounts-on-its-hepatitis-c-drugs-will-mean/.
7. Chhatwal J., Kanwal F., Roberts M.S., et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015, 162:397-406.
8. Linas B.P., Barter D.M., Morgan J.R., et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015, 162:619-629.
9. Najafzadeh M., Andersson K., Shrank W.H., et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015, 162:407-419.
10. Rein D.B., Wittenborn J.S., Smith B.D., et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015, 61:157-168.
11. Kuwabara H., Westerhout K., Treur M., et al. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naive chronic hepatitis C genotype 1 patients in Japan. J Med Econ 2015, 18:502-511.
12. Younossi Z.M., Park H., Saab S., et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015, 41:544-563.
13. Brogan A.J., Talbird S.E., Thompson J.R., et al. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One 2014, 9:e90295.
14. Chhatwal J., Ferrante S.A., Brass C., et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013, 16:973-986.
15. Ferrante S.A., Chhatwal J., Brass C.A., et al. Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013, 13:190.
16. Liu S., Cipriano L.E., Holodniy M., et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012, 156:279-290.
17. Chan K., Lai M.N., Groessl E.J., et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013, 11:1503-1510.
18. Ly K.N., Xing J., Klevens R.M., et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156:271-278.
19. Schackman B.R., Gebo K.A., Walensky R.P., et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006, 44:990-997.
20. Walensky R.P., Freedberg K.A., Weinstein M.C., et al. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis 2007, 45(Suppl 4):S248-S254.
21. Kaiser Family Foundation. US federal funding for HIV/AIDS: the President's FY 2015 budget request. Available: . Accessed: April 8, 2015. http://kff.org/global-health-policy/fact-sheet/u-s-federal-funding-for-hivaids-the-presidents-fy-2015-budget-request/.